KRAS-specific TCR-T cells

KRAS-specific TCR-T cells are a form of adoptive cell therapy in which a patient's own (autologous) or donor-derived (allogeneic) T cells are genetically engineered to express a transgenic T cell receptor (TCR) that specifically recognizes neoantigens derived from mutated KRAS proteins, most commonly the G12V mutation. These therapies are designed to target and kill cancer cells harboring specific KRAS mutations while sparing normal tissues expressing wild-type KRAS. The engineered TCRs bind to peptide-HLA complexes presenting mutant KRAS epitopes on tumor cell surfaces, leading to targeted cytotoxicity. Some advanced constructs co-express switch receptors such as PD1-41BB, which convert inhibitory signals from the tumor microenvironment into activating signals for enhanced anti-tumor activity and persistence[1][2][4][5]. This approach is being developed for solid tumors with high rates of KRAS mutations, including pancreatic ductal adenocarcinoma, non-small-cell lung cancer, and colorectal cancer.

Other names

KRAS mutant-specific TCR-T cellsmKRAS-specific TCR-T cellsmutant KRAS-targeted T cell receptor engineered T cell therapy